Treatment of Pleural and Peritoneal Carcinosis with Radioactive Colloids

  • G. Riccabona
Conference paper


The concept of treating effusions due to pleura or peritoneal carcinosis with radioactive colloids was introduced 40 years ago [2]. For this purpose, 63Zn sulfide and later on 198Au colloid have been used [2, 3]. Both cases involved the application of beta and gamma emitters, where the beta emission was almost exclusively responsible for the therapeutic effect. As the gamma radiation necessitated inconvenient precautions for radiation protection [1], radioactive colloids with pure beta emission have been developed since 1954 for intracavitary radionuclide therapy [4–7]. This concerned primarily 32P chromium phosphate and 90Y silicate; 169Er citrate and 186Re sulfate were also recommended. Whereas the two latter compounds were not applied on a large scale, the 90Y colloid has for almost 30 years proved to be the most suitable substance for the treatment of malignant effusions in pleura and peritoneum.


Malignant Pleural Effusion Beta Emission Malignant Effusion Cytostatic Treatment Peritoneal Carcinosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Becker J, Scheer KE (1961) Die lokalisierte Applikation künstlich radioaktiver Isotope. In: Höfer K (ed) Künstliche radioaktive Isotope in Physiologie, Diagnostik und Therapie, vol 2. Springer, Berlin Göttingen Heidelberg, p 702Google Scholar
  2. 2.
    Müller JH (1945) Über die Verwendung von künstlich radioaktiven Isotopen zur Erzielung von lokalisierten biologischen Strahlenwirkungen. Experientia 1:199CrossRefGoogle Scholar
  3. 3.
    Müller JH (1961) Interne Tumortherapie mit künstlich radioaktiven Isotopen. In: Künstliche radioaktive Isotope in Physiologie, Diagnostik und Therapie, vol 2. Springer, Berlin Göttingen Heidelberg, p 785Google Scholar
  4. 4.
    Riccabona G (1978) Intracavitäre Isotopentherapie, klinische Bedeutung in Diagnostik und Therapie. Nuc Med, p 698Google Scholar
  5. 5.
    Riccabona G (1983) Therapy with radionuclides — Actual state of the art. In: Nuclearmedi-cine, imaging of metabolism and organ function. Schattauer, Stuttgart, p 910Google Scholar
  6. 6.
    Root SW, Taylor MP, Andrews GA, Knisely RM (1954) Distribution of colloidal radioactive chromic phosphate after intracavitary administration. Radiology 63:251PubMedGoogle Scholar
  7. 7.
    Siegel EP, Hart HE, Brothers M, Spencer H, Laszlo D (1956) Radio-yttrium (90Y) for the palliative treatment of effusions due to malignancy. JAMA 161:499Google Scholar
  8. 8.
    Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 159:1704Google Scholar
  9. 9.
    Zaloznik AJ, Oswald SG, Langin M (1983) Intrapleural tetracycline in malignant pleural effusions, a randomized study. Cancer 51:752–755PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • G. Riccabona
    • 1
  1. 1.Universitätsklinik für NuklearmedizinInnsbruckAustria

Personalised recommendations